Matt T Bianchi1, Semmie Kim2, Thania Galvan2, David P White3, Hadine Joffe2,4,5. 1. Sleep Division, Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston, MA. 2. Women's Hormones and Aging Research Program, Department of Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 3. Brigham and Women's Hospital, Harvard Medical School, Boston, MA. 4. Department of Psychosocial Oncology and Palliative Care Medicine, Dana Farber Cancer Institute, Harvard Medical School, Boston, MA. 5. Center for Women's Mental Health, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA.
Abstract
STUDY OBJECTIVES: While women report sleep interruption secondary to nighttime hot flashes, the sleep disrupting impact of nocturnal hot flashes (HF) is not well characterized. We utilized a model of induced HF to investigate the relationship of nighttime HF to sleep architecture and sleep-stage transitions. METHODS: Twenty-eight healthy, premenopausal volunteers received the depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide to rapidly induce menopause, manifesting with HF. Sleep disruption was measured on 2 polysomnograms conducted before and after 4-5 weeks on leuprolide, when HF had developed. RESULTS: 165 HF episodes were recorded objectively during 48 sleep studies (mean 3.4 HF/night). After standardizing to sleep-stage time distribution, the majority of HF were recorded during wake (51.0%) and stage N1 (18.8%). Sixty-six percent of HF occurred within 5 minutes of an awakening, with 80% occurring just before or during the awakening. Objective HF were not associated with sleep disruption as measured by increased transitions to wake or N1, but self-reported nocturnal HF correlated with an increase from pre- to post-leuprolide in the rate of transitions to wake (p = 0.01), and to N1 (p = 0.008). CONCLUSIONS: By isolating the effect of HF on sleep in women without the confound of age-related sleep changes associated with natural menopause, this experimental model shows that HF arise most commonly during N1 and wake, typically preceding or occurring simultaneously with wake episodes. Perception of HF, but not objective HF, is linked to increased sleep-stage transitions, suggesting that sleep disruption increases awareness of and memory for nighttime HF events. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01116401.
STUDY OBJECTIVES: While women report sleep interruption secondary to nighttime hot flashes, the sleep disrupting impact of nocturnal hot flashes (HF) is not well characterized. We utilized a model of induced HF to investigate the relationship of nighttime HF to sleep architecture and sleep-stage transitions. METHODS: Twenty-eight healthy, premenopausal volunteers received the depot gonadotropin-releasing hormone agonist (GnRHa) leuprolide to rapidly induce menopause, manifesting with HF. Sleep disruption was measured on 2 polysomnograms conducted before and after 4-5 weeks on leuprolide, when HF had developed. RESULTS: 165 HF episodes were recorded objectively during 48 sleep studies (mean 3.4 HF/night). After standardizing to sleep-stage time distribution, the majority of HF were recorded during wake (51.0%) and stage N1 (18.8%). Sixty-six percent of HF occurred within 5 minutes of an awakening, with 80% occurring just before or during the awakening. Objective HF were not associated with sleep disruption as measured by increased transitions to wake or N1, but self-reported nocturnal HF correlated with an increase from pre- to post-leuprolide in the rate of transitions to wake (p = 0.01), and to N1 (p = 0.008). CONCLUSIONS: By isolating the effect of HF on sleep in women without the confound of age-related sleep changes associated with natural menopause, this experimental model shows that HF arise most commonly during N1 and wake, typically preceding or occurring simultaneously with wake episodes. Perception of HF, but not objective HF, is linked to increased sleep-stage transitions, suggesting that sleep disruption increases awareness of and memory for nighttime HF events. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01116401.
Authors: Nathaniel A Eiseman; M Brandon Westover; Joseph E Mietus; Robert J Thomas; Matt T Bianchi Journal: J Sleep Res Date: 2011-07-14 Impact factor: 3.981
Authors: Howard M Kravitz; Imke Janssen; Joyce T Bromberger; Karen A Matthews; Martica H Hall; Kristine Ruppert; Hadine Joffe Journal: Curr Sleep Med Rep Date: 2017-08-05
Authors: Katherine A Guthrie; Joseph C Larson; Kristine E Ensrud; Garnet L Anderson; Janet S Carpenter; Ellen W Freeman; Hadine Joffe; Andrea Z LaCroix; JoAnn E Manson; Charles M Morin; Katherine M Newton; Julie Otte; Susan D Reed; Susan M McCurry Journal: Sleep Date: 2018-01-01 Impact factor: 6.313
Authors: Dahima Cintron; Brian D Lahr; Kent R Bailey; Nanette Santoro; Robin Lloyd; JoAnn E Manson; Genevieve Neal-Perry; Lubna Pal; Hugh S Taylor; Whitney Wharton; Fredrick Naftolin; S Mitchell Harman; Virginia M Miller Journal: Menopause Date: 2018-02 Impact factor: 2.953